BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, a private investment group with venture, private equity and property investments.
In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Dr. Chan serves on the boards of Advanced Cell Diagnostics, Oxyrane, Stealth Peptides, Synchroneuron, Apellis, Nucana, VTI and Matrivax.
“Dr. Chan and Morningside were early supporters of Aduro and instrumental in funding our success to date,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Gerald is a highly respected executive, investor and an internationally renowned scientist. He has provided counsel to Aduro since 2011 and we are thrilled to have him formalize his advisory role with membership on our board of directors.”
Dr. Chan is a member of the Global Advisory Council of the International Society for Stem Cell Research, the Global Advisory Council of Harvard University, the Dean's Board of Advisors of the Harvard School of Public Health and the advisory boards of the Cold Spring Harbor Conferences Asia, the Johns Hopkins Nanjing Center and the Columbia University Center for Radiological Research. He is a trustee of Fudan University in Shanghai and chairs the Board of Overseers of Morningside College of the Chinese University of Hong Kong. He is a member of the Council on Foreign Relations, New York.
He received his BS and MS degrees in engineering from UCLA, his Master's degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. In 2011, the Chinese University of Hong Kong conferred on him an honorary Doctor of Social Science degree. He was the commencement speaker of the Harvard School of Public Health in 2012 and was elected to an honorary fellowship at Wolfson College of Oxford University in 2013.
Morningside, founded in 1986, is a diversified investment company with portfolio investments in private equity and technology ventures. The group invests actively in biotech companies founded on novel science.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a private, clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has ongoing clinical trials with its LADD platform in pancreatic cancer, mesothelioma and high-grade glioma and its immunotherapies are in development in non-small cell lung cancer, ovarian cancer and prostate cancer. The company is also developing clinical candidates using novel small molecules that activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.adurobiotech.com.